Anthracycline Cardiotoxicity in Adult Cancer Patients
Published: 17 September 2024
JACC: CARDIOONCOLOGY State-of-the-Art Review
Since their introduction in the 1960s, anthracyclines have been a significant breakthrough in oncology, introducing dramatic changes in the treatment of solid and hematologic malignancies. Although new-generation targeted drugs and cellular therapies are revolutionizing contemporary oncology, anthracyclines remain the cornerstone of treatment for lymphomas, acute leukemias, and soft tissue sarcomas.